According to the results of a clinical trial, two experimental vaccines against the Ebola virus have proved promising to protect from haemorrhagic fever for at least one year.
The results of the study published in the New England Journal of Medicine indicates that about 1,500 participants in Monrovia, Liberia received one of two vaccines being tested against Ebola or a placebo.
The first vaccine, rVSV-ZEBOV, was designed by Canadian government scientists and is now licensed by Merck, Sharp and Dohme Corporation. The second, AD3-EBOZ, was developed by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline.
After one month, 84% of patients vaccinated with rVSV-ZEBOV developed antibodies. After one year, 80% of them were still protected. For AD3-EBOZ, 71% developed antibodies after one month and 64% were still protected at the end of the test.
Some 15 vaccines under development
After receiving the vaccine, however, some people experienced mild side effects, such as headaches, muscle aches, fever and fatigue.
The trial was conducted as part of a clinical research collaboration between the United States and Liberia, known as the Ebola Partnership in Liberia (PREVAIL). The Ebola virus has killed more than 11,000 people, mainly in Liberia, Guinea and Sierra Leone between the end of 2013 and 2016.
Some 15 vaccines are being developed around the world against Ebola, a highly contagious virus. According to experts, the first vaccines could be approved by 2018, as part of an accelerated regulatory process.
Source: Jeune Afrique